3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Urinary Bladder Neoplasms
3
Carcinoma, Transitional Cell
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Muscle Invasive Bladder Cancer (MIBC)
1
Head and Neck Neoplasms
1
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
1
Gastric Adenocarcinoma
1
Endometrial Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Breast Cancer
1
Interventions
apatinib
2
Hyperthermic Intraperitoneal Chemotherapy
2
Gastrectomy
2
trastuzumab deruxtecan
1
taxane
1
durvalumab
1
disitamab vedotin
1
Taxes
1
SHR-1701
1
S 1 (combination)
1
Platinum
1
Paclitaxel
1
Oxaliplatin
1
Magnetic Resonance Spectroscopy
1
Indocyanine Green
1
Cytoreduction Surgical Procedures
1
Cisplatin
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastric Adenocarcinoma
×
disitamab vedotin
×
90 days
×
Clear all
NCT07507526
2026-04-02
DTP-HER2
Sun Yat-sen University
Phase 2
Not yet recruiting
76 enrolled